Regeneron Pharmaceuticals, Inc. (REGN)
| Market Cap | 77.89B +2.2% |
| Revenue (ttm) | 14.34B +1.0% |
| Net Income | 4.50B +2.1% |
| EPS | 41.48 +8.2% |
| Shares Out | 102.60M |
| PE Ratio | 18.30 |
| Forward PE | 17.04 |
| Dividend | $3.76 (0.50%) |
| Ex-Dividend Date | Feb 20, 2026 |
| Volume | 768,569 |
| Open | 745.53 |
| Previous Close | 755.02 |
| Day's Range | 742.74 - 773.72 |
| 52-Week Range | 476.49 - 821.11 |
| Beta | 0.41 |
| Analysts | Buy |
| Price Target | 808.88 (+6.55%) |
| Earnings Date | Jan 30, 2026 |
About REGN
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous sq... [Read more]
Financial Performance
In 2025, Regeneron Pharmaceuticals's revenue was $14.34 billion, an increase of 0.99% compared to the previous year's $14.20 billion. Earnings were $4.50 billion, an increase of 2.09%.
Financial StatementsAnalyst Summary
According to 24 analysts, the average rating for REGN stock is "Buy." The 12-month stock price target is $808.88, which is an increase of 6.55% from the latest price.
News
These Analysts Revise Their Forecasts On Regeneron Pharmaceuticals After Q4 Results
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) on Friday reported upbeat fourth-quarter earnings.
EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases
New presentations include final 64-week results from the Phase 3 QUASAR trial in patients with retinal vein occlusion, as well as full primary results from the Phase 3b ELARA trial in patients treated...
Regeneron: Expect Double-Digit Growth In 2026
Regeneron is poised for double-digit revenue and EPS growth in 2026, driven by Dupixent and reduced Eylea headwinds. Dupixent's robust expansion and pipeline successors support Regeneron's long-term g...
Regeneron Pharmaceuticals, Inc. (REGN) Q4 2025 Earnings Call Transcript
Regeneron Pharmaceuticals, Inc. (REGN) Q4 2025 Earnings Call Transcript
Regeneron bets added cholesterol benefit will help its obesity drug stand out
Regeneron Pharmaceuticals' executives voiced confidence in its experimental weight-loss drug on Friday, saying added cholesterol-lowering benefits could give the company an edge in an increasingly cro...
Regeneron Posts Lower Eylea Sales Amid Rising Competition, Plans $2 Billion New Factory
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) on Friday reported fourth-quarter adjusted earnings of $11.44 per share, down 5% year-over-year, beating the consensus of $10.71.
Regeneron beats quarterly profit estimates on Dupixent strength
U.S. drugmaker Regeneron Pharmaceuticals beat analysts' estimate for fourth-quarter profit on Friday, helped by strong demand for its eczema treatment, Dupixent.
Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
TARRYTOWN, N.Y., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the fourth quarter and full year 2025 and provided a business up...
Regeneron Pharmaceuticals Likely To Report Lower Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will release earnings results for its fourth quarter, before the opening bell on Friday, Jan. 30.
Regeneron: Q4 Earnings Preview - Why I'm Expecting A Beat And Strong 2026
Regeneron Pharmaceuticals, Inc. is approaching a pivotal earnings report following a strong JP Morgan Healthcare Conference update. I maintain a Buy rating on REGN, supported by a >16% share price gai...
Nation's Top 40 High School Scientists to Compete for $1.8 Million in Awards at the Prestigious Regeneron Science Talent Search
Society for Science & Regeneron announced the finalists in the Regeneron Science Talent Search, the nation's oldest and most prestigious STEM competition
Regeneron Pharmaceuticals, Inc. (REGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Regeneron Pharmaceuticals, Inc. (REGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Final Trades: Capital One, UnitedHealth, Regeneron and Alibaba
The Investment Committee give you their top stocks to watch for the second half.
Regeneron Just Moved From Underperform To Buy - Here's Why
Could the tide be turning for Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) after a surprising shift in analyst sentiment?
Press Release: Sanofi and Regeneron's Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma
Sanofi and Regeneron's Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma Approval based on global phase 3 program in children demonstrating Dupixent significantly reduce...
Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma
Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo
Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
TARRYTOWN, N.Y., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January ...
Regeneron: The Turnaround Is Gaining Steam
Regeneron Pharmaceuticals is poised for a turnaround as Eylea's patent cliff fades and new growth drivers emerge. Dupixent and Libtayo are expected to drive robust revenue and margin expansion, with D...
Calls of the Day: Regeneron, Booking Holdings, General Dynamics and Fiserv
The Investment Committee debate the latest Calls of the Day.
Regeneron Pharmaceuticals, Inc. (REGN) Discusses Lynozyfic Development Strategy and Pipeline Opportunities in Multiple Myeloma Transcript
Regeneron Pharmaceuticals, Inc. (REGN) Discusses Lynozyfic Development Strategy and Pipeline Opportunities in Multiple Myeloma Transcript
Health Rounds: Regeneron drug wipes out residual multiple myeloma cells in small trial
A recently approved antibody drug from Regeneron Pharmaceuticals eradicates residual traces of multiple myeloma after initial treatments, potentially allowing patients to avoid grueling bone marrow tr...
Regeneron Pharmaceuticals: Is Wall Street Finally Paying Attention?
Regeneron Pharmaceuticals once again beat consensus EPS and revenue estimates by a wide margin. Moreover, as of September 30, Regeneron had about $2.2 billion remaining under its authorized share repu...
Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment
All three dose groups (50 mg, 100 mg and 200 mg) showed impressive monotherapy efficacy, with VGPR+ (very good partial response or better) of ≥70% despite limited follow-up; evidence shows that these ...
Regeneron's experimental therapy combo effective in untreated cancer patients
Regeneron said on Saturday its experimental cancer combination therapy was effective and showed disappearance of the disease in previously untreated patients with a type of blood cancer in the first p...
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript